Pfizer veteran Ian Read to retire as executive chairman

(Reuters) – Pfizer Inc (N:) said on Friday Ian Read will retire as executive chairman at the end of this year, after a four-decade association with the largest U.S. drugmaker that included eight years as chief executive officer.

Company veteran Albert Bourla, who succeeded Read, will assume the additional role of chairman.

Read, 66, helped Pfizer weather patent expirations of several blockbusters, including cholesterol drug Lipitor, through dealmaking, expansion in emerging markets and cost cuts.

The drugmaker has since eschewed large, transformative deals because of confidence in the strength of its pipeline.

In July, Pfizer announced plans to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV (O:), a move that will help the company focus on its innovative drugs that generate more profit.

Separately, the drugmaker reported positive data from a late-stage study testing its experimental atopic dermatitis treatment, abrocitinib.

The company’s shares gained 0.6% at $36 in premarket trading.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.